ReShape Lifesciences Inc. financial data

Symbol
RSLS on Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
Location
1001 Calle Amanecer, San Clemente, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
OBALON THERAPEUTICS INC (to 6/21/2021)
Latest financial report
Q1 2024 - May 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 223 % +23.5%
Quick Ratio 84.6 % +73.7%
Debt-to-equity 83.5 % +53.9%
Return On Assets -113 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.5M shares +785%
Common Stock, Shares, Outstanding 23.5M shares +786%
Entity Public Float 5.07M USD -52.4%
Common Stock, Value, Issued 23K USD +667%
Weighted Average Number of Shares Outstanding, Basic 23.5M shares +1273%
Weighted Average Number of Shares Outstanding, Diluted 23.5M shares +1273%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.34M USD -24.8%
Research and Development Expense 2.35M USD +4.5%
General and Administrative Expense 7.98M USD -54.6%
Operating Income (Loss) -12M USD +72.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.9M USD +73.6%
Income Tax Expense (Benefit) 52K USD 0%
Net Income (Loss) Attributable to Parent -10.9M USD +73.2%
Earnings Per Share, Basic -0.44 USD/shares +99.5%
Earnings Per Share, Diluted -0.44 USD/shares +99.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.38M USD -73.5%
Accounts Receivable, after Allowance for Credit Loss, Current 1.6M USD
Inventory, Net 3.47M USD -0.74%
Other Assets, Current 70K USD -58.3%
Assets, Current 7.9M USD -48.2%
Deferred Income Tax Assets, Net 27K USD -52.6%
Property, Plant and Equipment, Net 54K USD -92%
Operating Lease, Right-of-Use Asset 226K USD +163%
Other Assets, Noncurrent 29K USD -49.1%
Assets 8.23M USD -49.7%
Accounts Payable, Current 1.31M USD -34.2%
Employee-related Liabilities, Current 602K USD -63.6%
Accrued Liabilities, Current 1.93M USD -63.7%
Liabilities, Current 3.52M USD -53.7%
Deferred Income Tax Liabilities, Net 367K USD -40.3%
Operating Lease, Liability, Noncurrent 127K USD
Liabilities 3.7M USD -57%
Accumulated Other Comprehensive Income (Loss), Net of Tax -96K USD -3.23%
Retained Earnings (Accumulated Deficit) -638M USD -1.74%
Stockholders' Equity Attributable to Parent 4.53M USD -41.6%
Liabilities and Equity 8.23M USD -49.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.07M USD +59.1%
Net Cash Provided by (Used in) Financing Activities 17.6M USD +461%
Net Cash Provided by (Used in) Investing Activities -10K USD +89.1%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 23.5M shares +786%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.08M USD -141%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.48M USD -72.7%
Deferred Tax Assets, Valuation Allowance 76.9M USD +5.42%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 77M USD +5.28%
Operating Lease, Liability 239K USD +178%
Depreciation 6K USD -83.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.9M USD +73.2%
Lessee, Operating Lease, Liability, to be Paid 258K USD +197%
Property, Plant and Equipment, Gross 150K USD -85.4%
Operating Lease, Liability, Current 112K USD +30.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 84K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +39.2%
Deferred Income Tax Expense (Benefit) 1K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19K USD +1800%
Lessee, Operating Lease, Liability, to be Paid, Year Three 59K USD
Deferred Tax Assets, Operating Loss Carryforwards 67.9M USD +7.11%
Deferred Federal Income Tax Expense (Benefit) -293K USD -34.4%
Preferred Stock, Shares Authorized 10M shares +100%
Unrecognized Tax Benefits 1.05M USD 0%
Operating Lease, Payments 27K USD -69%
Additional Paid in Capital 642M USD +1.21%
Current State and Local Tax Expense (Benefit) 7K USD -22.2%
Current Federal Tax Expense (Benefit) 30K USD
Amortization of Intangible Assets 33K USD -98.2%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -48.6%
Share-based Payment Arrangement, Expense 617K USD -61.2%
Deferred State and Local Income Tax Expense (Benefit) -76K USD -153%